Marimastat
Based on 21 publication(s) in Google Scholar
Marimastat (BB2516) is a broad spectrum and orally bioavailable inhibitor of MMPs, with potent activity against MMP-9 (IC50=3 nM), MMP-1 (IC50=5 nM), MMP-2 (IC50=6 nM), MMP-14 (IC50=9 nM) and MMP-7 (IC50=13 nM), used in the treatment of cancer. Marimastat (BB2516) is an angiogenesis and metastasis inhibitor, which limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.
For research use only. We do not sell to patients.
- Purity: 99.81%
- CAS No.: 154039-60-8
- Formula: C15H29N3O5
- Molecular Weight:331.41
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Differentiation Inducing Compound Library
HY-L038
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Targeted Diversity Library
HY-L099
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Pain-Related Compound Library
HY-L139
-
Protease Inhibitor Library
HY-L147
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Marimastat
More- Adv Mater. 2025 Sep 22:e12554. [Abstract]
- Cell Res. 2020 Sep;30(9):779-793. [Abstract]
- Sci Adv. 2025 Mar 14;11(11):eadu7614. [Abstract]
- Mol Ther. 2016 Dec;24(12):2090-2099.
- EMBO Rep. 2021 Jul 5;22(7):e51678. [Abstract]
- Cell Prolif. 2025 May 15:e70060. [Abstract]
- Int J Mol Sci. 2026 Jun 4;27(11):5104. [Abstract]
- Rheumatology (Oxford). 2025 Aug 13:keaf437. [Abstract]
- J Cell Mol Med. 2026 Apr;30(7):e71101. [Abstract]
- Bioconjug Chem. 2016 Dec 21;27(12):2943-2953. [Abstract]
- Biomed Mater. 2026 Jun 26. [Abstract]
- Viruses. 2022 Sep 21;14(10):2094. [Abstract]
- Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Apr 26:159618. [Abstract]
- Endocrine. 2021 May;72(2):529-538. [Abstract]
- PLoS One. 2024 Dec 27;19(12):e0315245. [Abstract]
- Eur Biophys J. 2021 May;50(3-4):345-352. [Abstract]
- bioRxiv. 2025 Jul 2:2025.07.01.662195. [Abstract]
- KTH Royal Institute of Technology. 2025.
- SSRN. 2020 Oct 5.
- ACS Comb Sci. 2019 Dec 9;21(12):805-816. [Abstract]
- Chinese Journal of Biochemical and Pharmaceutics. 2017,37(12):1-04.
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Histological Imaging/Staining
-
WB
-
Bio/Physico-chemical Assay
Biological Activity
|
MMP-3 3 nM (IC50) |
MMP-1 5 nM (IC50) |
MMP-2 6 nM (IC50) |
MMP-14 9 nM (IC50) |
MMP-7 13 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| THP-1 | IC50 |
2100 nM
Compound: 1Marimastat
|
Selective inhibition of the cellular TNF alpha release from LPS-stimulated THP-1 cells
Selective inhibition of the cellular TNF alpha release from LPS-stimulated THP-1 cells
|
[PMID: 11754593] |
Marimastat (BB2516) (1 μM) shows inhibition of vascular outgrowth, and selectively affects angiogenesis[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 154039-60-8
-
Appearance Solid
-
Molecular Weight 331.41
-
Formula C15H29N3O5
-
Color White to gray
-
SMILES
O=C(NO)[C@@H](O)[C@@H](CC(C)C)C(N[C@H](C(NC)=O)C(C)(C)C)=O
-
Synonyms
BB2516; TA2516
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (21)
-
Journal Impact Factor
-
Most Recent
-
Adv Mater
Spatiotemporally Engineered Protein Delivery via Integrated Covalent Coupling and Pathological Triggers for Precision Microenvironment Reprogramming in Tissue Injury Repair. [Abstract]2025 Sep 22:e12554. PMID: 40981608 -
Cell Res
s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide. [Abstract]2020 Sep;30(9):779-793. PMID: 32296111
Marimastat purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Sep;30(9):779-793. [Abstract]
HUVECs were treated with or without sorafenib or marimastat (1 μM) for 24 h. The level of s-HBEGF in the supernatant or pro-HBEGF in total cell lysates was detected by western blot.
-
Sci Adv
An enzymatic cleavage-triggered minimally invasive nanosensor for urine-based detection of early atherosclerosis. [Abstract]2025 Mar 14;11(11):eadu7614. PMID: 40085714
Marimastat purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Mar 14;11(11):eadu7614. [Abstract]
Fluorescence analysis of supernatant from foam cells treated with lipopolysaccharide and oxidized low-density lipoprotein, with or without Marimastat (10 μM), followed by incubation with the substrate peptide.
-
-
EMBO Rep
Sensing of mycobacterial arabinogalactan by galectin-9 exacerbates mycobacterial infection. [Abstract]2021 Jul 5;22(7):e51678. PMID: 33987949
Marimastat purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2021 Jul 5;22(7):e51678. [Abstract]
C57BL/6 mice were left untreated (NT) or were intraperitoneally treated with indicated amounts of AG for 3 days in the absence or presence of the MMP inhibitor marimastat (10 mg/kg) given intraperitoneally prior to AG stimulation. Lung sections stained with H&E and quantification of lung lesion burden from H&E‐stained sections .
-
Cell Prolif
LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants. [Abstract]2025 May 15:e70060. PMID: 40375579
Marimastat purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2025 May 15:e70060. [Abstract]
293T‐A2 cells were pretreated for 2 h with indicated concentrations of marimastat (0-10 μM), and then SARS‐CoV‐2 spike pseudoparticles pretreated for 2 h with 10 μg/mL of LL‐37 were added to cells. Infection rates were assessed at 2 days post infection by measuring the RLU of luciferase activity.
-
Int J Mol Sci
Epithelial PCSK6 Promotes Proliferation and Decreases Collagen Deposition by Fibroblasts Potentially via MMP Activation. [Abstract]2026 Jun 4;27(11):5104. PMID: 42278627 -
Rheumatology (Oxford)
Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]2025 Aug 13:keaf437. PMID: 40802538 -
J Cell Mol Med
2026 Apr;30(7):e71101. PMID: 41896195 -
Bioconjug Chem
Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy. [Abstract]2016 Dec 21;27(12):2943-2953. PMID: 27998073
Marimastat purchased from MedChemExpress. Usage Cited in: Bioconjug Chem. 2016 Dec 21;27(12):2943-2953. [Abstract]
Accumulative release of CPT from nanoparticles in different media: PBS buffer with MMP-2, PBS buffer, PBS buffer with MMP-2 and MMP-2 inhibitor Marimastat (1 mM).
Marimastat purchased from MedChemExpress. Usage Cited in: Bioconjug Chem. 2016 Dec 21;27(12):2943-2953. [Abstract]
Marimastat (1 μM). Representative photos of tumor spheroids after treatment with various formulations and blank controls, the scale bar is 100 μm.
Marimastat purchased from MedChemExpress. Usage Cited in: Bioconjug Chem. 2016 Dec 21;27(12):2943-2953. [Abstract]
Marimastat (1 μM). The ratio of volume change of HT-29 spheres volume (%) after applying different formulations. Data are represented as average ± standard error (n = 3).
-
Biomed Mater
3-Layer lung cancer invasion model for evaluating MMP-targeted anti-metastatic therapeutics. [Abstract]2026 Jun 26. PMID: 42361847 -
Viruses
Metalloprotease-Dependent S2'-Activation Promotes Cell-Cell Fusion and Syncytiation of SARS-CoV-2. [Abstract]2022 Sep 21;14(10):2094. PMID: 36298651 -
Biochim Biophys Acta Mol Cell Biol Lipids
2025 Apr 26:159618. PMID: 40294697 -
Endocrine
125I-Angiotensin 1-7 binds to a different site than angiotensin 1-7 in tissue membrane preparations. [Abstract]2021 May;72(2):529-538. PMID: 33415576 -
PLoS One
Discovery of novel TACE inhibitors using graph convolutional network, molecular docking, molecular dynamics simulation, and Biological evaluation. [Abstract]2024 Dec 27;19(12):e0315245. PMID: 39729480 -
Eur Biophys J
2021 May;50(3-4):345-352. PMID: 33864100 -
bioRxiv
Multimodal profiling of proinflammatory protease activity identifies caspase-1 as a target for lung cancer interception. [Abstract]2025 Jul 2:2025.07.01.662195. PMID: 40631193 -
-
-
ACS Comb Sci
Benzimidazolyl-pyrazolo[3,4- b]pyridinones, Selective Inhibitors of MOLT-4 Leukemia Cell Growth and Sea Urchin Embryo Spiculogenesis: Target Quest. [Abstract]2019 Dec 9;21(12):805-816. PMID: 31689077 -
Solvent & Solubility
DMSO : 100 mg/mL (301.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Compounds 1, 2, 7-9 and 11-16 are pre-incubated with MMP-1 or MMP-3 (10 nM) at different concentrations (0-10 μM) in a mixture of Tris-HCl (50 mM, pH 7.5), NaCl (150 mM), CaCl2 (10 mM), NaN3 (0.02%) and Brij-35 (0.05%) for 1 hour at 37°C. Residual activity is measured using the fluorogenic MMP substrate (2 μM) by fluorescence increase (emission at 393 nm and excitation at 325 nm) on a fluorescence plate reader. The data are fitted to the tight binding inhibitor equation: v=[(E-I-k+[(E-I-k)2+4Ek]1/2)/(2E)], where v is the velocity of the reaction, E is the enzyme concentration, I is the initial inhibitor concentration, and k is the apparent inhibition constant, using the software Prism.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Three-month-old female nude mice are inoculated using a trochar needle with 2 mm2 established SCC-1 tissue subcutaneously in the flank. Treatment started once the tumors are 5-6 mm in diameter. Mice are randomLy divided into groups of 8 mice to receive different treatments: (1) control, (2) marimastat alone, (3) cisplatin + radiation in combination and (4) marimastat + cisplatin + radiation in combination. All animalsreceive a 14-day osmotic pump containing dimethylsulfoxide (DMSO) as a control for both the pump and vehicle. Animals treated with marimastatreceive the same osmotic pump containing 200 μL of marimastat with DMSO to result in a daily dose of 8.7 mg/kg 10 days after the initiation of treatment. Lead-shielded animalsreceive 8 Gy of 60Co radiation to the exposed tumor, divided into 4 fractions on days 8, 12, 16 and 20. A dose of 8 Gy is chosen because 7.5 Gy (7,500 rad) has been shown in previous experiments to inhibit tumor growth without being a curative dose. Animals receive 4 intraperitoneal doses of cisplatin (3 mg/kg) 1 h before each fraction of radiation. Tumors are measured biweekly for 32 days. Potential treatment toxicity is monitored using mouse weight. Tumor size (surface area equal to product of two largest diameters) and regression rates are determined in each treatment group. After 32 days, tumors are harvested for immunohistochemistry. Day 32 is chosen due to death of control group animals and euthanization of animals showing clinical signs of illness to allow for statistical analysis of data acquired from surviving animals.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rasmussen HS, et al. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther. 1997;75(1):69-75. [Content Brief]
[2]. Yu M, et al. Incorporation of Bulky and Cationic Cyclam-Triazole Moieties into Marimastat Can Generate Potent MMP Inhibitory Activity without Inducing Cytotoxicity. ChemistryOpen. 2013 Jun;2(3):99-105. [Content Brief]
[3]. van Wijngaarden J, et al. An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510. Biochem Biophys Res Commun. 2010 Jan 8;391(2):1161-5. [Content Brief]
[4]. Skipper JB, et al. In vivo efficacy of marimastat and chemoradiation in head and neck cancer xenografts. ORL J Otorhinolaryngol Relat Spec. 2009;71(1):1-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0174 mL | 15.0871 mL | 30.1741 mL | 75.4353 mL |
| 5 mM | 0.6035 mL | 3.0174 mL | 6.0348 mL | 15.0871 mL | |
| 10 mM | 0.3017 mL | 1.5087 mL | 3.0174 mL | 7.5435 mL | |
| 15 mM | 0.2012 mL | 1.0058 mL | 2.0116 mL | 5.0290 mL | |
| 20 mM | 0.1509 mL | 0.7544 mL | 1.5087 mL | 3.7718 mL | |
| 25 mM | 0.1207 mL | 0.6035 mL | 1.2070 mL | 3.0174 mL | |
| 30 mM | 0.1006 mL | 0.5029 mL | 1.0058 mL | 2.5145 mL | |
| 40 mM | 0.0754 mL | 0.3772 mL | 0.7544 mL | 1.8859 mL | |
| 50 mM | 0.0603 mL | 0.3017 mL | 0.6035 mL | 1.5087 mL | |
| 60 mM | 0.0503 mL | 0.2515 mL | 0.5029 mL | 1.2573 mL | |
| 80 mM | 0.0377 mL | 0.1886 mL | 0.3772 mL | 0.9429 mL | |
| 100 mM | 0.0302 mL | 0.1509 mL | 0.3017 mL | 0.7544 mL |
Powered by Bioz